In current clinical practice, tumor localization in patients with biochemical recurrence (BCR) of prostate cancer is the most accepted and validated field of application of PET/CT with Ga-68 or F-18- prostate-specific membrane antigen (PSMA) ligands [1–3]. This evidence concerns the gene FOLH1 and prostate carcinoma.